Kyowa Kirin CoKYKOF 82 Return-on-Tangible-Asset is 18.55% as of Dec. 2025, which is 122% above its 10-year median of 8.37. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.76 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 79.2% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kyowa Kirin Co's annualizedNet Income for the quarter that ended in Dec. 2025 was $884 Mil. Kyowa Kirin Co's average total tangible assets for the quarter that ended in Dec. 2025 was $4,764 Mil. Therefore, Kyowa Kirin Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 18.55%.
The historical rank and industry rank for Kyowa Kirin Co's Return-on-Tangible-Asset or its related term are showing as below:
KYKOF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.17 Med: 8.37 Max: 11.83
Current: 10.3
During the past 13 years, Kyowa Kirin Co's highest Return-on-Tangible-Asset was 11.83%. The lowest was 6.17%. And the median was 8.37%.
KYKOF's Return-on-Tangible-Asset is ranked better than 79.2% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.17
vs KYKOF: 10.30
Kyowa Kirin Co (OTCPK:KYKOF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Kyowa Kirin Co Return-on-Tangible-Asset Related Terms
Kyowa Kirin Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KYKOF vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 18.55% mean?
Kyowa Kirin Co (KYKOF) has a Return-on-Tangible-Asset of 18.55% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kyowa Kirin Co and its competitors. This is 122% above median its historical median of 8.37. Over the past decade, Kyowa Kirin Co's Return-on-Tangible-Asset has ranged from 6.17 to 11.83. According to the industry distribution chart, Kyowa Kirin Co ranks #209 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Kyowa Kirin Co's Return-on-Tangible-Asset too high?
Kyowa Kirin Co's current Return-on-Tangible-Asset of 18.55% is 122% above median its 10-year median of 8.37. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 11.83. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.17. Kyowa Kirin Co's value of 18.55% is 485.2% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #209 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #209 out of 1005 companies for Return-on-Tangible-Asset. This places Kyowa Kirin Co in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.17. Kyowa Kirin Co's value of 18.55% is 485.2% above this benchmark. Historically, Kyowa Kirin Co's own Return-on-Tangible-Asset has ranged from 6.17 to 11.83 over the past decade. While the company's 10-year median is 8.37 vs. the industry median of 3.17, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.17, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current Return-on-Tangible-Asset of 18.55% is 485.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Return-on-Tangible-Asset is 18.55%, which is 122% above median its own 10-year median of 8.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.76, compared to a current price of $14.43 — trading 18.8% below its estimated fair value. The current Return-on-Tangible-Asset is 18.55%, which is 122% above median its 10-year median of 8.37 and 485.2% above the Drug Manufacturers industry median of 3.17. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Return-on-Tangible-Asset is 18.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 18.8% below its estimated GF Value™ of $17.76.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
Return-on-Tangible-Asset: 18.55% (122% above median its 10-year median of 8.37)
GF Value™: $17.76 vs. price of $14.43 (18.8% below fair value)
Industry Position: 485.2% above the Drug Manufacturers median (#209 of 1005)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
